Allergy, Asthma & Immunology Research最新文献

{"title":"Association Between Triglyceride-Glucose Index and Development of Asthma in US Adolescents: A Cross-Sectional Study.","authors":"Chuhan Cheng, Liyan Zhang","doi":"10.4168/aair.2024.16.6.640","DOIUrl":"10.4168/aair.2024.16.6.640","url":null,"abstract":"<p><strong>Purpose: </strong>Metabolic abnormalities, such as insulin resistance (IR) and dyslipidemia, have been linked to an increased risk of asthma. The triglyceride-glucose index (TyG), a metric indicating metabolic dysfunction, exhibits correlations with metabolic syndrome and IR. However, little research has been conducted on the relationship between TyG and asthma in the pediatric population. Therefore, we aimed to investigate the relationship between TyG and asthma among adolescents.</p><p><strong>Methods: </strong>Data from the National Health and Nutrition Examination Survey between 2007 and 2012 was analyzed in this cross-sectional study. The association between TyG and asthma was evaluated using various statistical methods, including multivariate logistic regression analysis, restricted cubic spline (RCS) analysis, threshold effects analysis, and subgroup analysis.</p><p><strong>Results: </strong>A total of 1,629 adolescent participants were enrolled in the study, consisting of 878 (53.9%) males and 751 females (46.1%), with a mean age of 15.5 years. After adjusting for all covariates in the multivariate logistic regression, the adjusted odds ratio (OR) for TyG and asthma in the highest quintile (Q5, > 8.65) was 4.26 (95% confidence interval [CI], 1.54, 11.81; <i>P</i> = 0.005) compared to the TyG in the second quintile (Q2, 7.68-7.96). Additionally, the multivariate RCS analysis revealed a non-linear relationship between TyG and asthma (<i>P</i> = 0.003). In the threshold analysis, the adjusted OR of asthma was 0.001 (95% CI, 0, 0.145; <i>P</i> = 0.007) in participants with a TyG < 7.78, and the adjusted OR of asthma was 3.685 (95% CI, 1.499, 9.058; <i>P</i> = 0.004) in participants with a TyG ≥ 7.78. Subgroup analysis did not show any interactive role for TyG and asthma.</p><p><strong>Conclusions: </strong>In US adolescents, a U-shaped association was observed between asthma and the TyG, with a critical turning point identified at around 7.78.</p>","PeriodicalId":7547,"journal":{"name":"Allergy, Asthma & Immunology Research","volume":"16 6","pages":"640-651"},"PeriodicalIF":4.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11621484/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142765455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can Vaccinations Trigger or Exacerbate Chronic Urticaria?","authors":"Young-Min Ye","doi":"10.4168/aair.2024.16.6.567","DOIUrl":"10.4168/aair.2024.16.6.567","url":null,"abstract":"","PeriodicalId":7547,"journal":{"name":"Allergy, Asthma & Immunology Research","volume":"16 6","pages":"567-570"},"PeriodicalIF":4.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11621475/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142765462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Toward Precision Medicine in Asthma-Chronic Obstructive Pulmonary Disease Overlap.","authors":"Chin Kook Rhee","doi":"10.4168/aair.2024.16.6.563","DOIUrl":"10.4168/aair.2024.16.6.563","url":null,"abstract":"","PeriodicalId":7547,"journal":{"name":"Allergy, Asthma & Immunology Research","volume":"16 6","pages":"563-566"},"PeriodicalIF":4.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11621482/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142765489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Montelukast+Levocetirizine Combination Therapy Compared to Montelukast Monotherapy for Allergic Rhinitis in Children.","authors":"Chang-Keun Kim, Yoonha Hwang, Dae Jin Song, Jinho Yu, Myung Hyun Sohn, Yong Mean Park, Dae Hyun Lim, Kangmo Ahn, Yeong-Ho Rha","doi":"10.4168/aair.2024.16.6.652","DOIUrl":"10.4168/aair.2024.16.6.652","url":null,"abstract":"<p><strong>Purpose: </strong>The combination therapy of leukotriene receptor antagonists and antihistamines may alleviate allergic rhinitis (AR) symptoms better than monotherapy. This study aimed to investigate the safety and efficacy of Monterizine^®, a fixed-dose combination of montelukast and levocetirizine, compared to montelukast monotherapy in pediatric patients with AR.</p><p><strong>Methods: </strong>One hundred seventy-six children aged 6 to 14 years with perennial AR symptoms were recruited. One hundred forty-seven subjects were randomized into 1 of 2 groups: the mont+levo group (fixed-dose combination of montelukast [5 mg] + levocetirizine [5 mg]) or the mont group (montelukast single agent [5 mg]). Study subjects took the treatment every evening for 4 weeks and recorded their daytime nasal symptom score (DNSS) and nighttime nasal symptom score (NNSS) in a diary every day. Adverse events (AEs) were also recorded, and patients were surveyed as to their overall satisfaction with the therapeutic product they received.</p><p><strong>Results: </strong>When DNSS and NNSS were assessed individually, daytime nasal congestion symptom scores decreased more in the mont+levo group during the 4-week treatment period than in the mont group (<i>P</i> = 0.0341). The daytime rhinorrhea symptom scores also decreased more in the mont+levo group (<i>P</i> = 0.0469). The nighttime nasal congestion score (severity when awake) decreased more in the mont+levo group than in the mont group (<i>P</i> = 0.0381). Study subjects in the mont+levo group experienced a greater improvement in quality of life than subjects in the mont group (<i>P</i> < 0.0001).</p><p><strong>Conclusions: </strong>The combination therapy of montelukast and levocetirizine was more effective in reducing both daytime nasal symptoms (nasal congestion and rhinorrhea) and nighttime nasal symptoms (severity of nasal congestion when awake). With fewer AEs and higher overall satisfaction, combination therapy is recommended for pediatric patients with perennial AR.</p>","PeriodicalId":7547,"journal":{"name":"Allergy, Asthma & Immunology Research","volume":"16 6","pages":"652-667"},"PeriodicalIF":4.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11621474/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142765479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inverse Trend Between Tree Pollen and Fungal Concentrations With Allergic Sensitization Rates in Seoul for 25 Years.","authors":"Young-Jin Choi, Kyung-Suk Lee, Jae-Won Oh","doi":"10.4168/aair.2024.16.6.571","DOIUrl":"10.4168/aair.2024.16.6.571","url":null,"abstract":"<p><p>A growing number of individuals are developing allergic diseases due to pollen exposure. Seasonal variations and increased pollen concentrations have occurred with the increased rates of allergic sensitization among both children and adults. Temperature significantly influences pollination, particularly in spring- and early summer-flowering plants, with weather conditions affecting pollen allergen levels. Human activities, including agriculture and deforestation, increase carbon emissions, leading to higher atmospheric CO₂ levels that may enhance allergenic plant productivity. Climate change affects the range of allergenic plant species and length of pollen season. Studies indicate that higher CO₂ and temperature levels are linked to increased pollen concentrations and allergenicity, whereas atmospheric fungal concentrations have declined annually over the past 25 years. Despite more intense precipitation in summer and autumn, the number of rainy days has decreased across all seasons. This concentration of rainfall over shorter periods likely prolongs the dry season and shortens the period of fungal sporulation. Future climate changes, including atmospheric dryness, drought, and desertification could further decrease allergenic fungal sporulation. It remains unclear whether the inverse relationship between pollen and fungal concentrations and distributions directly results from climate change. It is crucial to evaluate the patterns of aeroallergens and their associated health risks.</p>","PeriodicalId":7547,"journal":{"name":"Allergy, Asthma & Immunology Research","volume":"16 6","pages":"571-584"},"PeriodicalIF":4.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11621478/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142765485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Revisiting T Cells in Chronic Rhinosinusitis.","authors":"Sungmin Moon, Min-Seok Rha","doi":"10.4168/aair.2024.16.6.585","DOIUrl":"10.4168/aair.2024.16.6.585","url":null,"abstract":"<p><p>A variety of immune cells in the nasal tissue are involved in the immunopathogenesis of chronic rhinosinusitis (CRS), a chronic inflammatory disease affecting the nasal cavity and paranasal sinuses. T cells play a pivotal role in orchestrating immune dysregulation in CRS by producing key cytokines. Recent studies have expanded the understanding of T cell biology across the inflammatory endotypes of CRS. This review summarizes current knowledge on the multifaceted roles of T cells in the pathophysiology of CRS. Particularly, we highlight the alterations in phenotypes and functions of various T cell subsets in CRS. Additionally, as functional studies of effector and regulatory T cell populations have revealed potential translational targets, we suggest perspectives for future research into T cell-oriented therapeutic strategies for CRS.</p>","PeriodicalId":7547,"journal":{"name":"Allergy, Asthma & Immunology Research","volume":"16 6","pages":"585-600"},"PeriodicalIF":4.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11621483/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142765488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global Burden of Vaccine-Associated Chronic Urticaria, 2010-2023: From the Global Pharmacovigilance Database.","authors":"Jeewoo Kang, Jaeyu Park, Hyesu Jo, Hyeri Lee, Kyeongmin Lee, Soeun Kim, Jiseung Kang, Jun Hyuk Lee, Nikolaos G Papadopoulos, Lee Smith, Ju-Young Shin, Masoud Rahmati, Seong H Cho, Joong Ki Cho, Sooji Lee, Damiano Pizzol, Seung Geun Yeo, Hayeon Lee, Seon-Pil Jin, Dong Keon Yon","doi":"10.4168/aair.2024.16.6.613","DOIUrl":"10.4168/aair.2024.16.6.613","url":null,"abstract":"<p><strong>Purpose: </strong>The etiology and pathophysiology of vaccine-associated chronic urticaria (CU) remain unclear, particularly during the coronavirus disease 2019 (COVID-19) pandemic. Thus, this study aimed to comprehensively investigate the global burden and long-term trends of vaccine-associated CU, with a focus on the associated vaccines and the distribution of cases across different age groups and sexes.</p><p><strong>Methods: </strong>Using data from the World Health Organization international pharmacovigilance database (VigiBase), which encompasses reports from 156 countries and territories between 1968 and 2023, we systematically analyzed the global burden and long-term trends in vaccine-associated CU reports (total individual case safety reports = 131,255,418). We estimated the global and regional reports, information component (IC) with IC_0.25 using disproportionality analyses, and reporting odds ratio (ROR) with 95% confidence interval (CI) to investigate the potential associations between 27 vaccines and CU.</p><p><strong>Results: </strong>Among the 3,474 reports of all-cause CU, 1,898 vaccine-associated CU reports were identified between 2010 and 2023. A dramatic surge in vaccine-associated CU reports has been observed since 2020, primarily driven by the COVID-19 mRNA vaccines. The COVID-19 mRNA vaccines were associated with the most CU reports (ROR, 26.52 [95% CI, 24.33-28.90]; IC, 3.18 [IC_0.25, 3.10]), followed by papillomavirus (ROR, 4.23 [95% CI, 2.55-7.03]; IC, 1.93 [IC_0.25, 1.06]), influenza (ROR, 3.09 [95% CI, 2.16-4.43]; IC, 1.57 [IC_0.25, 0.96]), Ad5-vectored COVID-19 (ROR, 2.82 [95% CI, 2.40-3.31]; IC, 1.42 [IC_0.25, 1.16]), and zoster vaccines (ROR, 2.28 [95% CI, 1.32-3.93]; IC, 1.12 [IC_0.25, 0.18]). These increased risks were particularly pronounced for males and older adults. No fatal outcomes have been reported in vaccine-associated CU.</p><p><strong>Conclusions: </strong>This study underscores the importance of clinicians considering the potential risk factors associated with vaccine-associated CU, especially in the context of COVID-19-related vaccines. Ongoing pharmacovigilance efforts facilitated by robust reporting systems are required to further validate our findings.</p>","PeriodicalId":7547,"journal":{"name":"Allergy, Asthma & Immunology Research","volume":"16 6","pages":"613-625"},"PeriodicalIF":4.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11621480/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142765484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Distinct Clinical Profiles of IgE and IgG Autoantibodies to Thyroid Peroxidase in Chronic Spontaneous Urticaria.","authors":"Jae-Hyuk Jang, Yi-Kui Xiang, Eun-Mi Yang, Ji-Hyun Kim, Boyoun Choi, Hae-Sim Park, Marcus Maurer, Young-Min Ye","doi":"10.4168/aair.2024.16.6.626","DOIUrl":"10.4168/aair.2024.16.6.626","url":null,"abstract":"<p><strong>Purpose: </strong>In chronic spontaneous urticaria (CSU), autoimmune thyroid disease is the most common autoimmune comorbidity, and many CSU patients have immunoglobulin (Ig)E or IgG autoantibodies to thyroid peroxidase (TPO). It remains unclear how anti-TPO IgE and IgG autoantibodies are linked to each other and are associated with CSU features, activity, and therapeutic responses.</p><p><strong>Methods: </strong>CSU patients (n = 146, 92 females, mean age 42.9 years) and healthy normal controls (NCs, n = 30) were assessed for anti-TPO IgE and IgG by enzyme-linked immunosorbent assay, and the clinical and laboratory profiles, disease activity (UAS7), and response to 3 months of H1-antihistamine treatment were evaluated for anti-TPO IgE-positive and/or IgG-positive patients.</p><p><strong>Results: </strong>Among 146 CSU patients, 67 (46%, NCs: 6.6%) had elevated anti-TPO IgE and/or IgG, and 32 (22%), 35 (24%), and 5 (3%) had elevated anti-TPO IgE, anti-TPO IgG, and both, respectively. Of the patients with anti-TPO IgE and/or IgG, 44% (n = 27) had anti-TPO IgE but not IgG, 48% (n = 30) had anti-TPO IgG but not IgE, and only 8% (n = 5) had anti-TPO IgE and IgG. Compared to anti-TPO IgE-negative patients, anti-TPO IgE-positive ones had greater rates of atopy and antihistamine responses and lower disease activity (UAS7). Anti-TPO IgG-positive patients had greater rates of angioedema and elevated levels of anti-thyroglobulin IgG than anti-TPO IgG-negative patients.</p><p><strong>Conclusions: </strong>Forty-six percentages of CSU patients have autoantibodies to TPO; most have either IgE or IgG autoantibodies but not both. Anti-TPO IgE and anti-TPO IgG come with distinct CSU profiles, including treatment responses.</p>","PeriodicalId":7547,"journal":{"name":"Allergy, Asthma & Immunology Research","volume":"16 6","pages":"626-639"},"PeriodicalIF":4.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11621479/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142765477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations Between Skin Microbiome and Metabolome in the Pathogenesis of Atopic Dermatitis Patients With Scalp Involvement.","authors":"Suyeon Kim, Dong Ho Suh, Sunyoung Lee, Hei Sung Kim, Sang Hyun Cho, Yu Ri Woo","doi":"10.4168/aair.2024.16.6.668","DOIUrl":"10.4168/aair.2024.16.6.668","url":null,"abstract":"<p><strong>Purpose: </strong>Atopic dermatitis (AD) is a chronic inflammatory skin condition influenced by various factors, such as the skin microbiome and metabolome. However, specific contributions of these factors to scalp involvement in AD still need to be explored. In this study, we aimed to assess the associations between the skin microbiome and metabolome in AD patients with scalp dermatitis and healthy controls (HCs).</p><p><strong>Methods: </strong>A total of 20 AD patients with scalp involvement and 16 HCs were recruited, and their skin samples were collected for analysis. Bioinformatic analysis and 16S rRNA metagenomic sequencing were performed, with gas chromatography time-of-flight mass spectrometry (GC-TOF-MS) conducted for AD-associated skin metabolites. Spearman correlation analysis was used to identify the correlations between AD-associated skin bacteria and metabolites.</p><p><strong>Results: </strong>The results revealed significant differences in bacterial taxa and metabolites between the lesional and non-lesional scalp skin samples of AD patients (groups LS and NL, respectively) and those of HCs (group HC). Notably, group LS showed a significantly increased relative abundance of the genus <i>Staphylococcus</i> and a decreased abundance of <i>Cutibacterium</i> compared to group HC. The reduced abundance of <i>Cutibacterium</i> was also observed when comparing LS to NL. The GC-TOF-MS analysis identified 33 significantly decreased metabolites and 17 significantly increased metabolites in groups LS and NL compared with group HC. Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis revealed that amino acid-related metabolism was significantly altered in the metabolic pathway between groups LS, NL, and HC. Furthermore, Spearman correlation analysis showed significant correlations of the altered bacteria genera and skin metabolites between the 3 groups.</p><p><strong>Conclusions: </strong>The results of this research provide valuable insights into the associations the skin microbiome and metabolome between groups LS, NL, and HC. Identifying these specific contributions may offer new avenues for understanding the pathogenesis of scalp involvement in AD patients and potentially lead to improving management strategies.</p>","PeriodicalId":7547,"journal":{"name":"Allergy, Asthma & Immunology Research","volume":"16 6","pages":"668-681"},"PeriodicalIF":4.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11621476/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142765458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combined Dupilumab and Allergen-Specific Immunotherapy in Severe Refractory Atopic Dermatitis.","authors":"Jemin Kim, Jihee Boo, Hyunwoo Jang, Yeon Woo Jung, Jihee Kim, KeLun Zhang, Chang Ook Park","doi":"10.4168/aair.2024.16.6.682","DOIUrl":"10.4168/aair.2024.16.6.682","url":null,"abstract":"<p><p>Although combining allergen immunotherapy with biologics has shown promise in treating atopic diseases such as asthma and allergic rhinitis, atopic dermatitis (AD) remains notably underexplored in this context. This study aimed to investigate the efficacy and safety of combining dupilumab with subcutaneous immunotherapy (SCIT) for severe AD refractory to standard treatments. This was a single-center retrospective analysis assessing patients with severe AD treated with combined dupilumab and SCIT, dupilumab, or SCIT alone at the Severance Hospital, Seoul, Korea. The inclusion criteria encompassed severe AD diagnosis, specific immunoglobulin (Ig) E levels to house dust mite allergens, and treatment follow-up for at least 18 months. Eczema Area and Severity Index (EASI) scores, serum biomarker levels, and adverse event records were regularly collected. Forty-eight patients with AD were analyzed, showing significant improvement in EASI scores and favorable changes in serum biomarkers over 144 weeks. The combination therapy led to a sustained reduction in AD severity, a significant reduction in total IgE and specific IgE levels, and an increment in allergen-specific IgG4. All patients experienced only mild and temporary side effects, not requiring treatment discontinuation. Combining dupilumab with SCIT offers a promising therapeutic option for patients with severe, treatment-refractory AD, reducing disease severity and inducing favorable immunological changes without increasing adverse effects.</p>","PeriodicalId":7547,"journal":{"name":"Allergy, Asthma & Immunology Research","volume":"16 6","pages":"682-689"},"PeriodicalIF":4.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11621481/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142765474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}